Efficacy and Safety of Bromfenac Ophthalmic Solution
- First Posted Date
- 2008-01-04
- Last Posted Date
- 2013-02-15
- Lead Sponsor
- Bausch & Lomb Incorporated
- Target Recruit Count
- 568
- Registration Number
- NCT00585975
- Locations
- 🇺🇸
ISTA Pharmaceuticals, Inc., Irvine, California, United States
Safety and Efficacy of Intravitreal Fluocinolone Acetonide Implants in Patients With Diabetic Macular Edema
Phase 2
Completed
- Conditions
- Diabetic Macular Edema
- Interventions
- Procedure: standard of care laser photocoagulation
- First Posted Date
- 2007-12-19
- Last Posted Date
- 2011-12-08
- Lead Sponsor
- Bausch & Lomb Incorporated
- Target Recruit Count
- 40
- Registration Number
- NCT00576459
- Locations
- 🇮🇳
LV Prasad Eye Institute, Banjara Hills, Hyderabad, India
🇨🇳The Chinese University of Hong Kong, Hong Kong, China
Loteprednol Etabonate Opthalmic Suspension for the Treatment of Dry Eye
Phase 2
Completed
- Conditions
- Dry Eye
- Interventions
- First Posted Date
- 2007-11-20
- Last Posted Date
- 2011-07-18
- Lead Sponsor
- Bausch & Lomb Incorporated
- Target Recruit Count
- 119
- Registration Number
- NCT00560638
- Locations
- 🇺🇸
Ophthalmic Research Associates, Andover, Massachusetts, United States
Ocular Tolerance and Intraocular Pressure (IOP) Effects of Zylet Versus Tobradex
Phase 4
Completed
- Conditions
- Inflammation
- Interventions
- First Posted Date
- 2007-09-21
- Last Posted Date
- 2011-12-08
- Lead Sponsor
- Bausch & Lomb Incorporated
- Target Recruit Count
- 310
- Registration Number
- NCT00532961
Efficacy of Fluocinolone Acetonide Intravitreal Implant in Diabetic Macular Edema
Phase 2
Completed
- Conditions
- Diabetic Macular Edema
- Interventions
- Procedure: Standard of Care
- First Posted Date
- 2007-07-17
- Last Posted Date
- 2013-11-28
- Lead Sponsor
- Bausch & Lomb Incorporated
- Target Recruit Count
- 196
- Registration Number
- NCT00502541
Safety and Efficacy of Fluocinolone Acetonide Intravitreal Implant vs Standardized Therapy
Phase 2
Completed
- Conditions
- Non-infectious Uveitis
- Interventions
- Drug: corticosteroids and immunosuppressants
- First Posted Date
- 2007-05-03
- Last Posted Date
- 2011-12-08
- Lead Sponsor
- Bausch & Lomb Incorporated
- Target Recruit Count
- 140
- Registration Number
- NCT00468871
Safety and Efficacy of Fluocinolone Acetonide Intravitreal Implant
Phase 2
Terminated
- Conditions
- Non-infectious Uveitis
- Interventions
- First Posted Date
- 2007-04-05
- Last Posted Date
- 2011-12-08
- Lead Sponsor
- Bausch & Lomb Incorporated
- Target Recruit Count
- 239
- Registration Number
- NCT00456482
Zylet vs TobraDex in Blepharokeratoconjunctivitis
Phase 4
Completed
- Conditions
- Blepharokeratoconjunctivitis
- Interventions
- First Posted Date
- 2007-03-14
- Last Posted Date
- 2011-12-09
- Lead Sponsor
- Bausch & Lomb Incorporated
- Target Recruit Count
- 276
- Registration Number
- NCT00447577
- Locations
- 🇺🇸
Cornerstone Eye Care, High Point, North Carolina, United States
Dose-Finding Study Comparing the Safety and Efficacy of Latanoprost to a Novel Treatment for Glaucoma
Phase 2
Completed
- Conditions
- Primary Open Angle GlaucomaOcular HypertensionPigmentary GlaucomaPseudoexfoliative Glaucoma
- Interventions
- First Posted Date
- 2007-03-01
- Last Posted Date
- 2020-09-14
- Lead Sponsor
- Bausch & Lomb Incorporated
- Target Recruit Count
- 176
- Registration Number
- NCT00441883
- Locations
- 🇺🇸
Pfizer Investigational Site, Austin, Texas, United States
Evaluation of the Onset and Duration of Action of Bepotastine Besilate Ophthalmic Solution in Acute Allergic Conjunctivitis
Phase 2
Completed
- Conditions
- Conjunctivitis, Allergic
- Interventions
- First Posted Date
- 2007-01-19
- Last Posted Date
- 2013-02-15
- Lead Sponsor
- Bausch & Lomb Incorporated
- Target Recruit Count
- 107
- Registration Number
- NCT00424398
- Locations
- 🇺🇸
ISTA Pharmaceuticals, Inc., Irvine, California, United States
© Copyright 2025. All Rights Reserved by MedPath